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A p p e n d i x  A
Cell surface heparan sulfate proteoglycan Glypican-1 and placodal ganglion
formation
A.1     Abstract
Biochemical studies have implicated a specific interaction between a cell surface
heparan sulfate proteoglycan (HSPG), Glypican-1 (GPC1), and Slits in rat brain lysate
(Liang et al., 1999; Ronca et al., 2001). However, the link between glypicans and Slit-Robo
signaling in vivo during development remains elusive. More specifically, the mechanism of
the Slit1 distribution and its reception by Robo2 on trigeminal placodal neurons may rely
on a co-receptor, such as GPC1, but this process is unknown. To more deeply investigate
the nature of Slit1–Robo2 signaling, we sought to characterize the potential role of GPC1
during cranial sensory ganglia formation. In this chapter, we show that GPC1 mRNA is
expressed in the placodal cells at the right time and place for a role during cranial
gangliogenesis, and additionally the expression of GPC1 on early migrating hindbrain
neural crest cells also indicate a possibility for its role in the neural crest. GPC1 gain-of-
function caused both reduced and disorganized placodal neurons at early assembly and
later severely reduced trigeminal ganglion at times of condensation. In extreme cases, this
caused elimination of nearly the entire ophthalmic lobe of the ganglion. The data so far
suggest that proper regulation of GPC1 expression is essential for placodal ganglion
formation and that GPC1 function is sufficient to affect placodal cell survival and/or
proliferation, and possibly morphogenesis. In summary, the results show a previously
unknown expression and potential role for a glypican family member in both neural crest
and placodal development. These provide an exciting outlook for further exploration on the
function of GPC1 and the general role of HSPGs in neural crest and cranial sensory ganglia
development.
A.2    Introduction
 Glypicans (GPCs) constitute one of two major families of cell surface heparan
sulfate proteoglycans (HSPGs). The other family is the syndecans which are
transmembrane proteins as compared to the glypicans which are anchored to the membrane
through a glycosyl-phosphatidylinositol (GPI) link. There are six members of glypicans
(GPC1-6) in mammals, two in Drosophila melanogaster (Dally and Dally-like), two in
Caenohabiditis elegans (gpn-1 and lon-2), and one in zebrafish (knypek) (Fico et al., 2007)
which have so far been identified. The core protein of the glypican molecules are well
conserved which consist of a large globular cysteine-rich domain, a smaller domain
encompassing the heparan sulfate (HS) attachment sites, and a sequence signal for the GPI
attachment (Filmus and Song, 2000). On the glypican core protein, HS side chains are
attached near the membrane anchor and are thought to facilitate binding of heparin-binding
growth factors and ligands. Therefore, glypicans are considered co-receptors for various
signals and possibly act to regulate the distribution and activity of these factors.
Additionally, however, there is also a possibility for glypican functions independent of its
HS side chain. Overexpression of GPC3 can induce apoptosis in a cell line specific manner
but this does not require its HS chains (Gonzalez et al., 1998). Furthermore, multiple types
of post-translational processing can take place on glypicans, such as complex modifications
of the HS chains and proteolytic cleavage at the GPI anchor or at the N-terminal cysteine-
rich domain, which can yield tissue-specific as well as non-cell-autonomous effects as
reviewed in (Fico et al., 2007).
During vertebrate development, glypicans are known to be expressed in a
spatiotemporally regulated manner in the nervous system as well as in various other tissues
(Litwack et al., 1998; Luxardi et al., 2007; Niu et al., 1996; Saunders et al., 1997). Their
expression also changes in pathological cases, such as cancer. GPC3 and/or GPC1 have
been found to be either downregulated in some ovarian cancer and mesothelioma cell lines
(Lin et al., 1999; Murthy et al., 2000) or upregulated in others (e.g. pancreatic tumors)
(Filmus, 2001; Kleeff et al., 1998; Matsuda et al., 2001; Su et al., 2006).
The functions of proteoglycans during embryonic development are profound.
Functional perturbation of glypicans in mice, Xenopus laevis, Drosophila, and zebrafish
has been shown to affect Wingless/Wnt, Dpp/BMP, Fgf and/or Hh signaling in affecting
cell fates, body size, cell movements (e.g. during gastrulation), cell survival and
proliferation (Fico et al., 2007; Filmus and Song, 2000). Loss of function mutations in
OCI-5/GPC3 in humans cause the Simpson-Golabi-Behmel syndrome (SGBS), which is
characterized by pre- and post- natal overgrowth and visceral and skeletal defects and an
increased risk for tumors (Pilia et al, 1996). GPC3 knockout mouse model also exhibit
similar phenotypes (Cano-Gauci et al., 1999). The first Drosophila homolog for glypican,
division abnormally delayed (dally) gene, was found in a screen for defects in cell division
patterning in the forming CNS (Nakato et al., 1995). dally mutants have delayed G2–M
transition in dividing cells in the eye disc and lamina as well as defects in morphogenesis of
adult tissues (i.e. the eye, antenna, wing, and genitalia) and viability. Dally-like, the second
glypican member in Drosophila, has been shown to facilitate long range Wingless
signaling by transporting the signal to neighboring cells in the wing imaginal disc, while
Dally acts as classical co-receptor (Franch-Marro et al., 2005). In terms of regulation of cell
proliferation, the effects of glypican in vertebrates appear to be the opposite of that in the
fly, such that glypican-3 is a negative regulator whereas dally promotes cell division. Taken
together, genetic evidence from glypican mutants implicate functions for glypican in
regulating cell survival, proliferation, and/or morphogenesis, likely reflecting its
association with a wide range of major signaling pathways. How specificity is conferred in
a spatiotemporal manner that link the function of a proteoglycan to a particular signaling
pathway on a cell remains to be uncovered.
Recent evidence have implicated direct interaction of heparan sulfate proteoglycans
(HSPGs) with Slit for its function (reviewed in (Hohenester, 2008)). Structural studies have
suggested a Slit–Robo–HS complex based on the result that the second leucine rich repeat
of Slit binds to heparin and both can bind to Robo (Fukuhara et al., 2008; Hussain et al.,
2006). Disruption of heparan sulfate (HS) chains by heparinase decreases affinity of
Slit–Robo binding and also blocks Slit repulsive activity in vitro (Hu, 2001; Piper et al.,
2006). Consistent with this, when excess HS is applied to compete with endogenous HS,
Slit activity is also compromised in a growth cone collapse assay (Piper et al., 2006).
Genetic evidence from Drosophila, also indicate the interaction of syndecan, a HSPG, with
Slit–Robo in regulating distribution and efficiency of Slit signaling (Johnson et al., 2004;
Steigemann et al., 2004). In vertebrates, the role of syndecan with Slit–Robo has not been
characterized, but recombinant vertebrate Glypican-1 has been found to bind specifically to
Slit1 and Slit2 from rat brain extracts in a heparan sulfate dependent manner (Liang et al.,
1999; Ronca et al., 2001). The functional relationship of HSPG and Slit–Robo in vivo is
unknown.
We have previously identified the critical role of Slit1–Robo2 in mediating neural
crest-placode assembly of the trigeminal ganglion as presented in Chapter 2. The nature of
the slit ligand reception and distribution required for proper gangliogenesis remains
unexplored. The biochemical interaction reported for Glypican-1 and Slit1 prompted us to
wonder if there may be a possible connection between GPC1 and Slit1–Robo2 signaling
during trigeminal gangliogenesis. The expression and function of glypicans during cranial
gangliogenesis have not been investigated previously. As a first step, we sought to explore
whether Glypican-1 may be involved in neural crest and/or placode development. We
characterized the gene expression pattern of Glypican-1 during cranial gangliogenesis and
we found that trigeminal and epibranchial placodal cells and early hindbrain neural crest
cells express Glypican-1 at the time of ganglion assembly and crest migration, respectively.
The results show a previously unknown expression of a glypican family member which is
potentially involved in both neural crest and placodal development. Furthermore the proper
expression level of Glypican-1 in the placodal tissue appears to be crucial for formation of
the trigeminal ganglion. Overexpression of GPC1 causes both reduced and disorganized
placodal neurons at early assembly and severely reduced trigeminal ganglion later at times
of coalescence. In extreme cases, this caused elimination of nearly the entire ophthalmic
lobe of the ganglion. The data so far suggest that proper regulation of GPC1 expression is
essential for placodal ganglion formation and provide a basis for further exploration on its
function in neural crest and cranial sensory ganglia development.
A. 3   Materials and Methods
Embryos
Fertilized chicken (Gallus gallus domesticus) eggs were obtained from local commercial
sources and incubated at 37°C to the desired stages according to the criteria of Hamburger
and Hamilton (Hamburger and Hamilton, 1992).
In situ hybridization
Whole mount chick in situ hybridization was performed as described (Shiau et al., 2008).
cDNA plasmids obtained from BBSRC (ChickEST clone 418p2) was used to transcribe the
antisense riboprobe against chick Glypican-1. The plasmid was sequenced and determined
to contain the coding sequence of the chick Glypican-1 gene (NCBI accession number:
XM_422590.1) corresponding to nucleotides 1233-2107. Embryos were imaged and
subsequently sectioned at 12 µm.
Immunohistochemistry
Whole chick embryos were fixed in 4% paraformaldehyde overnight at 4ºC, washed in
PBT (PBS + 0.2% tween) and either immunostained as whole embryos and/or processed
for 10 µm cryostat sections. Primary antibodies used were anti-HNK-1 (American Type
Culture; 1:3 or 1:5), anti-Islet1 (DSHB, clone 40.2D6; 1:250), and anti-TuJ1 (Covance;
1:250). Secondary antibodies were obtained from Molecular Probes and used at 1:1000 or
1:2000 dilutions, except 1:250 dilution for Alexa Flour 350 conjugated antibodies. Images
were taken using the AxioVision software from a Zeiss Axioskop2 plus fluorescence
microscope, and processed using Adobe Photoshop CS3.
In ovo electroporation of the trigeminal ectoderm
DNA was injected overlying the presumptive trigeminal placodal ectoderm at stages 8–10
by air pressure using a glass micropipette. Platinum electrodes were placed vertically
across the chick embryo delivering 5 × 8 V in 50 ms at 100 ms intervals current pulses.
Electroporated eggs were re-sealed and re-incubated at 37˚C to reach the desired stages (i.e.
30–36 hours to stages 15–16 and 36–48 hours to stages 17–19).
Plasmid constructs
Full length chick Glypican-1 cDNA (clone CS5) was isolated from a 4– to 12– somites
stage chick macroarray library as previously described (Gammill and Bronner-Fraser,
2002). The coding sequence (1.65 kb) was amplified from the library clone by PCR using a
5’ primer with a flanking a XhoI site and a 3’ primer with a flanking ClaI site. This
fragment was inserted into PCRII-Topo vector using the TOPO TA cloning kit (Invitrogen)
and clone G1 (PCRII-Topo  + GPC1, size = 5.65 kb) was determined to be correct by
sequencing. The fragment was then digested at the XhoI/ClaI sites and directionally cloned
into the XhoI/ClaI sites in the cyto-pcig vector, yielding clones CG2 and CG3 (cytopcig +
GCP1, size = 7.8 kb) which were determined to be correct by sequencing.
A.4    Results and discussions
A.4.1   Expression of Glypican-1 mRNA in the precursors of cranial sensory ganglia
suggests its potential role in ganglion formation
To investigate whether Glypican-1 (GPC1) may have a role during cranial
gangliogenesis, I have characterized the mRNA expression of GPC1 in the chick embryo at
stages 9–18 by whole mount in situ hybridization (Fig. 1). This represents the time window
prior to or at the beginning of neural crest migration up to ganglion condensation. In the
presumptive trigeminal region, the neural crest cells migrating at the midbrain and anterior
hindbrain (R1/R2) level starting at stage 9 through stages 13–14 do not appear to express
GPC1 (Fig. 1, A-C, E). At stages 12–13, low levels of GPC1 were sometimes detected in
the ectoderm bilateral to the midbrain region in a salt-and-pepper pattern indicative that it
may be in trigeminal placodes (data not shown) but this remains to be confirmed. Later, at
stages 14–16 during trigeminal ganglion assembly, GPC1 is expressed by both the
ophthalmic (OpV) and maxillo-mandibular (MmV) placodes that form the trigeminal
ganglion (Fig. 1, E-F). To confirm that these GPC1 expressing cells are in fact placode-
derived, I have labeled the placodal ectoderm with GFP by ectoderm electroporation prior
to its ingression and collected these embryos at later stages to process for GPC1 in situ
hybridization. Results show that all GFP expressing placode-derived cells and discrete
regions of the placodal ectoderm express GPC1 (Fig. 1, G-K), while they interact with the
trigeminal neural crest cells which do not. The matching expression pattern of GPC1 and
Robo2 as previously described (Shiau et al., 2008) in the trigeminal placodal cells lends a
possibility for GPC1 to act as a co-receptor in regulating Slit1–Robo2. Alternatively, GPC1
may have an independent function during trigeminal gangliogenesis. This expression
pattern may be conserved with the mammalian GPC1 as it is also expressed in the
peripheral cranial and trunk sensory ganglia (i.e. trigeminal and dorsal root) in mouse and
rat embryos (Litwack et al., 1998), though the distinction between the neural crest and
placode cell types was not made.
The expression pattern is somewhat different in the hindbrain region corresponding
to the presumptive epibranchial ganglia region, which is at around the second to the fourth
branchial arches. Unlike the trigeminal neural crest, GPC1 is detected in the hindbrain
neural crest cells during migration (Fig. 1, C-D), albeit expression is transient, since by
stage 14, it is downregulated (Fig. 1, L-M).  In addition, GPC1 is expressed in the
epibranchial placodal ectoderm at later stages 14–16 (Fig. 1, E-F and L-M). The expression
pattern of GPC1 in the hindbrain region suggests that it may potentially have an early role
in hindbrain neural crest migration and later in epibranchial placodal gangliogenesis.
A.4.2   Expression of Glypican-1 mRNA in other tissues, including the neural tube, otic
vesicle, limb, and somite
Expression of GPC1 mRNA was found in several other tissues besides the neural
crest and placodal cells at stages 9–18. GPC1 was weakly expressed in the forming neural
tube and notochord throughout these stages at the cranial levels (Fig. 1, A-L). By stage 12,
the otic placode is found to express GPC1 albeit weakly but later through stage 18, its
expression is strong in the invaginating and forming otic vesicle (Fig. 1, C, E-F, L, P). The
forming limb bud also expresses GPC1 (Fig. 1P). Among these, the tissue expressing
GPC1 in the most dynamic manner is probably the somitic tissue. Through the stages
examined (st. 9–18), the GPC1 mRNA appears to be expressed in a gradient fashion in the
presomitic mesoderm (PSM) highest at the newly forming somites and decreases both
rostrally (towards the more anterior somites) and caudally towards the tail of the embryo.
The expression found for GPC1 may suggest potentially interesting functions both early in
specifying segmentation of the anterior PSM and later in epithelialization or boundary
formation of the newly forming somite. The different expression of GPC1 from that of
Robo2 and Slit1 in the trunk region, such that Robo2 is expressed in the neural folds and
restricted portions of the somites similar to Slit1 (data not shown) (De Bellard et al., 2003),
suggests that GPC1 may interact with signaling pathways other than Slit–Robo in the
somites (Fig. 1, N-P). These expression patterns of GPC1 were consistent with that found
previously in the forming neural tube, somite, and limb (Niu et al., 1996). It is also
important to note that since Niu et al. examined mostly different stages (st.7–12 and
20–25), we have identified several previously unknown expression patterns of GPC1,
including its expression in the cranial ganglia. They also characterized expressions of
GPC1 that were not studied here at later stages 20–25, including expression of GPC1 in the
mantle zone of the telencephalon, apical epidermal ridge, the proximal limb,
atrioventricular canal, and in the heart outflow tract which they suggest is endothelial- and
not neural crest- derived mesenchyme.
A.4.3   Overexpression of Glypican-1 causes early disorganization of trigeminal placodal
neurons and later severely reduced ganglion
The expression of Glypican-1 in the placodal ectoderm and derived cells as the
trigeminal ganglion assembles suggests a possibility for its function in placodal
gangliogenesis. To begin to test the function of GPC1, I have designed a full-length chick
Glypican-1 expression construct (cytopcig + GPC1) and introduced it in the trigeminal
placodal ectoderm prior to ingression at stages 8–10 to study the effects of GPC1 gain-of-
function on ganglion formation. Strikingly, overexpression of GPC1 in the trigeminal
placodal cells caused severe reduction in placodal cell number, giving rise to diminished
ganglia, as well as effects on placodal assembly at early stages. At times of early ganglion
assembly (stages 15–16), a significant number of transfected ganglia showed aberrant
defects (77%, n=7/9). These defects were classified into two general groups: either both
disorganized (aberrant positioning) and reduced in cell number (33%, n= 3/9) (Fig. 2D-F)
or only appeared reduced in cell number (44%, n=4/9) (Fig. 2G-I). Later after the ganglion
is well condensed at stages 17–19, the transfected ganglia with GPC1 overexpression were
severely reduced in cell number and/or disorganized (69%, n=11/16). Out of the total
number of ganglia exhibiting a phenotype, 82% (n=9/11) of the cases were diminished
ganglia (Fig. 2M-O) of which 44% (n=4/9) had nearly complete loss of the ophthalmic
(OpV) lobe (Fig. 2P-R). The loss of OpV phenotype thus constituted a significant 25%
(n=4/16) of the total GPC1 transfected ganglia analyzed at stages 17–19. Control
untransfected sides of the GPC1 electroporated embryos and control GFP electroporated
embryos did not show apparent ganglion abnormalities at all stages analyzed (Fig. 2, A-C
and J-L and data not shown).
The results suggest an intriguing possibility that GPC1 may have a role in
regulating placodal cell survival and/or proliferation and possibly also cell organization.
The potential effect on cell proliferation may reflect a role for GPC1 on neuronal
differentiation of the placodal cells, which takes place in the placodal ectoderm prior to
ingression. This is based on the fact that most, if not all, placodal cells express neuronal
markers by the time they ingress. Furthermore, it is intriguing to examine whether
ingression may be affected such that a blocked migration may cause a reduced number of
placodal neurons; however, this may be a secondary effect to loss of neuronal
differentiation. Alternatively if undifferentiated placodal cells are aberrantly found to
migrate to the ganglion anlage by GPC1 overexpression, this would demonstrate that
migration and differentiation can be uncoupled, but this is unknown. Taken together, the
data suggest that GPC1 function is sufficient to affect several aspects of the development of
the placodal neurons during trigeminal ganglion formation, which likely involves various
signaling pathways.
A.5   Conclusion and future work
The gene expression pattern and gain-of-function of GPC1 suggest its potential role
in development of the trigeminal placodal ganglion. GPC1 was also expressed in the early
migrating hindbrain neural crest cells and the epibranchial placodes but its role in these
cells has not yet been examined.  There are several lines of future research that would be
important to fully uncover the role of GPC1 in neural crest and placode development in the
future.
First, understanding the cellular and molecular mechanisms mediated by GPC1
gain-of-function in causing the severe phenotype of trigeminal ganglion loss would provide
important insights into the function of GPC1. It would be necessary to clarify the cellular
effects as to whether this effect is on placodal cell survival, proliferation, and/or
differentiation and also whether it alters placodal cell assembly. To identify the molecular
mechanism responsible for mediating this function, it would be important to first identify
the protein domain of GPC1 required for this phenotype, whether this requires the HS chain
or not. Function of the core glypican protein has been suggested previously (i.e. transient
expression of GPC-3 can induce apoptosis and this requires membrane anchorage but not
the heparan sulfate chains (Gonzalez et al., 1998)). This suggests a potential role for GPC1
independent of its HS based co-receptor function. Overexpression of GPC1 may have an
effect on Slit1 signaling or on other pathways (e.g. Wnt (Lassiter et al., 2007) and Fgf
signaling (Stark et al., 2000)) implicated in trigeminal placodal development. Thus, the
examination of whether this alters distribution of the protein expression patterns of these
ligands and whether this may activate pathway specific downstream mediators would be
revealing on the potential association of GPC1 to the different signaling pathways.
To further reveal its function, it would also be important to identify the subcellular
localization and the potential proteolytic processing of the GPC1 proteins in these cells.
Since an antibody against chick GPC1 that works for immunohistochemistry may not be
available, the characterization of the exogenous GPC1 tagged with a reporter may yield
useful information as to its localization on the cell membrane and/or possibly in the nucleus
(which has been suggested but remains to be verified (Filmus and Song, 2000; Liang et al.,
1997)) as well as its potential post-translational modifications (i.e. proteolytic cleavage at
the GPI anchor or at a different site).
Gene knockdown of GPC1 in the trigeminal and epibranchial placodal cells as well
as in the hindbrain neural crest would be necessary to uncover its endogenous role during
development of the peripheral nervous system. Finally, the interaction between GPC1 and
Slit1–Robo2 signaling can be tested by exploring whether altering GPC1 expression
changes Slit1 expression and also if they are functionally interdependent (i.e. does gain or
loss of function of Slit1 or Robo2 rescue the GPC1 mutant phenotype and vice versa).
Further work on any of these future directions would undoubtedly provide new insights
into the role of HSPG and its potential link with signaling pathways involved in placode
and neural crest development.
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Figure 1.  Glypican-1 mRNA expression in trigeminal and epibranchial placodes,
hindbrain neural crest, and various other tissues. GPC1 mRNA expression is revealed by
whole mount in situ hybridization using an antisense chick GPC1 riboprobe. (A) Stage 9
chick embryo revealing a dynamic rostrocaudal gradient of GPC1 expression in the
presomitic mesoderm (PSM) (black and gray arrowheads) and a strong expression in the
neural tube (arrow). (B) Stage 10 embryo revealing the same gradient expression in the
PSM (black and gray arrowheads). (C) Stage 12 embryo showing expression in the neural
tube (arrow) and in the hindbrain neural crest at rhombomere 4 (dotted line). (D) Cross
section at the level indicated by the dotted line in C. (E) Stage 14 and (F) stage 16 embryos
showing expression in the OpV and MmV trigeminal and epibranchial placodes and otic
vesicle. (G) Cross section at the level indicated in E showing the expression of GPC1 in the
OpV placodes (dotted box) and weakly in the neural tube. (H) Overlay image showing
overlap of GFP expression in the ectoderm and ectoderm-derived cells and GPC1 in situ
expression (white arrowheads), and expression of GPC1 in an area of the placodal
ectoderm not electroporated by GFP vector (gray arrowheads). Images of the same section
as in H showing (I) GPC1 expression alone, (J) GFP expression alone and (I) overlay of
GFP and neural crest marker HNK-1 expression. (L) Cross section at the level indicated in
E showing GPC1 expression in the epibranchial placode (arrowheads), weakly in the
hindbrain neural crest (arrows), otic vesicle, neural tube, and notochord. (M) Same section
as in L showing HNK-1 expression on the hindbrain neural crest cells that also express
GPC1 (arrows). (N) Expression of GPC1 and (O) Robo2 mRNA in the trunk regions of
stage 14 embryos showing a mostly non-overlapping pattern. (P) Whole mount stage 16
embryo showing GPC1 expression in the limb bud as well as all other tissues
aforementioned. OpV, ophthalmic; MmV, maxillo-mandibular; ot, otic vesicle; nt, neural
tube; no, notochord; nc,  neural crest; nf, neural folds.
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Figure 2.  GPC1 overexpression in the trigeminal placodal ectoderm causes early
disorganization of the placodal neurons and later severely reduced ganglion. Color overlay
panel showing GFP (green) expression in area of transfection and double immunostaining
for broad neuronal markers Islet1 (red) and TuJ1 (blue) to reveal placodal neuronal cell
bodies and processes, respectively. Representative images of GPC1 electroporated embryos
analyzed at stages 15-16 showing (A-C) a typical trigeminal ganglion on the control
untransfected side, and aberrant GPC1 transfected ganglia which displayed two general
categories of phenotypes: (D-F) severely disorganized and reduced population of placodal
neurons (arrows) or (G-I) only markedly reduced population of the placodal neurons
(arrow showing the OpV region). Later at stages 17-19, (J-L) control untransfected side
(which had a small region of GFP expression but predominantly not in the ganglion region)
showing normal ganglion formation, whereas the GPC1 transfected ganglia showed (M-O)
dramatically reduced ganglion with some disorganization (arrows) and in extreme cases (P-
R) near complete loss of the OpV lobe (asterisk) and a reduced MmV (arrow) ganglion.
OpV, ophthalmic; MmV, maxillo-mandibular.
